Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Ambulatory or hospitalized patients coming from the cardiology clinic of the participating hospitals
Adult patients ≥ 18 years old with a confirmed diagnosis of non-valvular atrial fibrillation
Patients must in addition present with at least one of following risk factors:
prior stroke, TIA (transient ischemic attack) or non-CNS (central nervous system) systemic embolism
left ventricular ejection fraction of < 40%
symptomatic heart failure, New York Heart Association class 2 or higher
age ≥75 years
age ≥65 years in combination with either diabetes, coronary disease or arterial hypertension
Patients who do not fulfil the Belgian reimbursement criteria